A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors.

Filip Janku,Milind M Javle,Shiraj Sen,Shubham Pant,Lindsay G Bramwell,Vivek Subbiah,Tracey Way,David S Wages,Catherine A Wheeler,Takeaki Suzuki,Kazunori Saeki,Ruth Ann Subach,Timothy Madden,Gary Maier,Mary J Johansen,Kin Cheung,Gerald S Falchook

Cancer（2023）

引用 0|浏览33

暂无评分

摘要

FF-10502-01 was well tolerated with manageable side effects and limited hematologic toxicity. Durable PRs and disease stabilizations were observed in heavily pretreated biliary tract patients who had received prior gemcitabine. FF-10502-01 is distinct from gemcitabine and may represent an effective therapy.

查看译文

关键词

BAP1,FF-10502-01,PBRM1,antimetabolite,cholangiocarcinoma,nucleoside,solid tumors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要